Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology

Martin Hoenigl, Jon Salmanton-García, Thomas J. Walsh, Marcio Nucci, Chin Fen Neoh, Jeffrey D. Jenks, Michaela Lackner, Rosanne Sprute, Abdullah M.S. Al-Hatmi, Matteo Bassetti, Fabianne Carlesse, Tomas Freiberger, Philipp Koehler, Thomas Lehrnbecher, Anil Kumar, Juergen Prattes, Malcolm Richardson, Sanjay Revankar, Monica A. Slavin, Jannik StemlerBirgit Spiess, Saad J. Taj-Aldeen, Adilia Warris, Patrick C.Y. Woo, Jo Anne H. Young, Kerstin Albus, Dorothee Arenz, Valentina Arsic-Arsenijevic, Jean Philippe Bouchara, Terrence Rohan Chinniah, Anuradha Chowdhary, G. Sybren de Hoog, George Dimopoulos, Rafael F. Duarte, Petr Hamal, Jacques F. Meis, Sayoki Mfinanga, Flavio Queiroz-Telles, Thomas F. Patterson, Galia Rahav, Thomas R. Rogers, Coleman Rotstein, Retno Wahyuningsih, Danila Seidel, Oliver A. Cornely

Research output: Contribution to journalArticlepeer-review

Abstract

With increasing numbers of patients needing intensive care or who are immunosuppressed, infections caused by moulds other than Aspergillus spp or Mucorales are increasing. Although antifungal prophylaxis has shown effectiveness in preventing many invasive fungal infections, selective pressure has caused an increase of breakthrough infections caused by Fusarium, Lomentospora, and Scedosporium species, as well as by dematiaceous moulds, Rasamsonia, Schizophyllum, Scopulariopsis, Paecilomyces, Penicillium, Talaromyces and Purpureocillium species. Guidance on the complex multidisciplinary management of infections caused by these pathogens has the potential to improve prognosis. Management routes depend on the availability of diagnostic and therapeutic options. The present recommendations are part of the One World-One Guideline initiative to incorporate regional differences in the epidemiology and management of rare mould infections. Experts from 24 countries contributed their knowledge and analysed published evidence on the diagnosis and treatment of rare mould infections. This consensus document intends to provide practical guidance in clinical decision making by engaging physicians and scientists involved in various aspects of clinical management. Moreover, we identify areas of uncertainty and constraints in optimising this management.

Original languageEnglish (US)
Pages (from-to)e246-e257
JournalThe Lancet. Infectious diseases
Volume21
Issue number8
DOIs
StatePublished - Aug 1 2021

Bibliographical note

Publisher Copyright:
Copyright © 2021 Elsevier Ltd. All rights reserved.

Fingerprint

Dive into the research topics of 'Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology'. Together they form a unique fingerprint.

Cite this